Publications by authors named "Sara Zawadzka-Leska"
Article Synopsis
- Azacitidine (AZA) is the primary treatment for higher-risk myelodysplastic syndrome (HR-MDS) patients who cannot undergo intensive therapy, but outcomes can vary between clinical trials and real-life applications.
- A study involving 315 patients treated with AZA showed that 24% experienced early treatment failure, with serum albumin levels serving as a key predictor for this outcome.
- Overall, the study concluded that evaluating serum albumin levels prior to treatment can help identify patients at higher risk for early failure and worse survival outcomes.
